Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.020
+0.060 (1.52%)
At close: Apr 28, 2026, 4:00 PM EDT
4.030
+0.010 (0.25%)
Pre-market: Apr 29, 2026, 6:26 AM EDT
Precigen Employees
Precigen had 160 employees as of December 31, 2025. The number of employees increased by 17 or 11.89% compared to the previous year.
Employees
160
Change (1Y)
17
Growth (1Y)
11.89%
Revenue / Employee
$60,525
Profits / Employee
-$2,685,263
Market Cap
1.42B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Maze Therapeutics | 141 |
PGEN News
- 22 days ago - Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - Accesswire
- 4 weeks ago - Precigen Transcript: Fireside chat - Transcripts
- 4 weeks ago - Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - PRNewsWire
- 4 weeks ago - These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
- 4 weeks ago - Precigen Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Precigen Reports Full Year 2025 Financial Results and Business Updates - PRNewsWire
- 6 weeks ago - Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 - PRNewsWire
- 3 months ago - New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire